

Practitioner's Docket No. 58610 (71432)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: B. Hansen et al.

Application No. 10/776,934

Filed February 10, 2004

Group No.: 1614

Examiner: Not Yet Assigned

For: **OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION**




Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATION UNDER 37 C.F.R. 1.10*

(Express Mail label number is mandatory.)

(Express Mail certification is optional.)

I hereby certify that this Completion of Filing Requirements and the papers indicated as being transmitted therewith is being deposited with the United States Postal Service on this date July 14, 2004, in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EV438993369US, addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, Mail Stop PCT.

Lee Dunkle
(type or print name of person mailing paper)

Lee Dunkle
Signature of person mailing paper

WARNING: *Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.*

***WARNING:** *Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R 1.10(b).*

"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §§1.56 and 1.97, Applicants herewith submit the publications and/or patents shown on the attached form PTO-1449, for consideration by the Examiner in connection with the examination of the above-identified patent application.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

X (1) within three (3) months of the Filing Date or **before the mailing date of the First Office Action** on the merits; or

B. Hansen et al.
U.S.S.N. 10/776,934
Page 2

- (2) within three months of the mailing date of the Written Opposition issued by the: _____ Patent Office (dated _____); or
- (3) after the period defined in (1) but before the mailing date of a Final Rejection or Notice of Allowance, and the requisite Certification or fee under Rule 1.17(p), namely \$180.00, is included herein; or
- (4) after the mailing date of a Final Rejection or Notice of Allowance but before the payment of the Issue Fee, and the requisite Certification, petition, and petition fee are included herein.

It is respectfully requested that each of the documents shown on the attached form(s) PTO-1449 be made of record in this application. Copies of these documents (CHECK ONE):

are enclosed herewith; or
 have been cited in the parent application, and are thus not being resubmitted herein.

Early examination and allowance of the present application are respectfully solicited.

FEE AUTHORIZATION

Should any fees associated with the submission be required, the Commissioner is authorized to charge the missing fee to our Deposit Account, No. 04-1105. Any overpayments should be credited to said Deposit Account.

Respectfully submitted,


Christine C. O'Day (Reg. 38,256)
Edwards & Angell, LLP
P.O. Box 55874
Boston, MA 02205
(617) 439-4444

Date: 7-14-04



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		DOCKET NO.: 58610 (71432)		SERIAL NO.: 10/776,934		
		APPLICANT(S): B. Hansen et al.				
		FILING DATE: February 10, 2004		GROUP NO.: 1614		

UNITED STATES PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	US 6,117,848	9/12/00	Monia et al.	514	44	
	AB	US 5,874,416	2/23/99	G. Sheikhnejad	514	44	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO
	BA	WO 98/50540	11/12/98	WIPO			
	BB	WO 99/22772	5/14/99	WIPO			
	BC	WO 99/02732	1/21/99	WIPO			
	BD	WO 98/49349	11/5/98	WIPO			
	BE	WO 94/28720	12/22/94	WIPO			
	BF	WO 94/08003	4/14/94	WIPO			
	BG	WO 92/22651	12/23/92	WIPO			
	BH	WO 03/095467 A1	11/20/03	WIPO			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

CA	Pedersen et al., <i>Synthesis</i> , No. 6, pp. 802-808 (2002)
CB	Sørensen et al., <i>J. Am. Chem. Soc</i> , pp. 2164-2176 (2002)
CC	Singh et al., <i>J. Org. Chem</i> , Vol. 63, No. 18, pp. 6078-6079 (1998)
CD	Rosenbohm et al., <i>Org. Biomol. Chem</i> , Vol. 1, pp. 655-663 (2003)
CE	Chin et al., <i>Nature</i> , Vol. 400, pp. 468-472 (1999)
CF	Gray et al. <i>Cancer Research</i> , Vol. 53, pp. 577-580 (1993)

Examiner: _____ Date: _____

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		DOCKET NO.: 58610 (71432)		SERIAL NO.: 10/776,934	
		APPLICANT(S): B. Hansen et al.			
		FILING DATE: February 10, 2004		GROUP NO.: 1614	

UNITED STATES PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	CG	Schwab et al. <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 10460-10464 (1994)
	CH	Bennett et al. <i>Antisense Therapeutics</i> , pp. 16-27 (1996)
	CI	Cowser, <i>Anti-Cancer Drug Design</i> , Vol. 12, pp. 359-371 (1997)
	CJ	Cunningham et al., <i>Amer. Cancer Soc.</i> , Vol. 92, pp. 1265-1271 (2001)
	CK	Freier et al., <i>Nucl. Acid Res.</i> , Vol. 25, pp. 4429-4443 (1997)
	CL	Uhlmann et al, <i>Curr. Opinion in Drug Discovery & Development</i> , Vol. 3, No.2, pp. 203-213 (2000)

Examiner:	Date:
-----------	-------